
## Terence C Chua

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11982071/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Intraoperative macroscopic tumour consistency is associated with overall survival after cytoreductive surgery and intraperitoneal chemotherapy for appendiceal adenocarcinoma with peritoneal metastases: A retrospective observational study. American Journal of Surgery, 2019, 217, 704-712.	0.9	10
2	Histological Subtype Remains a Significant Prognostic Factor for Survival Outcomes in Patients With Appendiceal Mucinous Neoplasm With Peritoneal Dissemination. Diseases of the Colon and Rectum, 2017, 60, 360-367.	0.7	37
3	Repeat cytoreductive surgery with or without perioperative intraperitoneal chemotherapy for peritoneal surface malignancy. American Journal of Surgery, 2017, 213, 1024-1030.	0.9	2
4	Physical and chemical characteristics of mucin secreted by pseudomyxoma peritonei (PMP). International Journal of Medical Sciences, 2017, 14, 18-28.	1.1	19
5	lleocecal Intussusception Caused by an Appendiceal Neoplasm. Journal of Gastrointestinal Surgery, 2016, 20, 867-868.	0.9	7
6	Impacts of Preoperative Serum Albumin Level on Outcomes of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy. Annals of Surgical Oncology, 2016, 23, 2411-2418.	0.7	12
7	Impacts of peritoneal cancer index on the survival outcomes of patients with colorectal peritoneal carcinomatosis. International Journal of Surgery, 2016, 32, 65-70.	1.1	21
8	Hepatobiliary and Pancreatic: Dual system stenting of the biliary and porto-venous systems to palliate locoregional recurrence of hilar cholangiocarcinoma. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1239-1239.	1.4	0
9	Pancreatic Metastasectomy—an Analysis of Survival Outcomes and Prognostic Factors. Journal of Gastrointestinal Surgery, 2016, 20, 1188-1193.	0.9	3
10	Prognostic Significance of Ki67 Expression in Malignant Peritoneal Mesothelioma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 388-394.	0.6	25
11	Effect of Nonparallel Placement of In-Circle Bipolar Radiofrequency Ablation Probes on Volume of Tissue Ablated With Heat Sink. Surgical Innovation, 2015, 22, 223-234.	0.4	2
12	Endovascular stenting of mesenterico-portal vein stenosis to reduce blood flow through venous collaterals prior to pancreatoduodenectomy. Langenbeck's Archives of Surgery, 2015, 400, 629-631.	0.8	5
13	MUC1 as a Potential Target in Anticancer Therapies. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 108-118.	0.6	54
14	Impacts of low peritoneal cancer index on the survival outcomes of patient with peritoneal carcinomatosis of colorectal origin. International Journal of Surgery, 2015, 23, 181-185.	1.1	23
15	Heat Sink Phenomenon of Bipolar and Monopolar Radiofrequency Ablation Observed Using Polypropylene Tubes for Vessel Simulation. Surgical Innovation, 2014, 21, 269-276.	0.4	30
16	A commentary on concurrent MCL1 and JUN amplification in pseudomyxoma peritonei: a comprehensive genetic profiling and survival analysis. Journal of Human Genetics, 2014, 59, 176-177.	1.1	0
17	A formulation for <i>in situ</i> lysis of mucin secreted in pseudomyxoma peritonei. International Journal of Cancer, 2014, 134, 478-486.	2.3	41
18	Impact of Prior Hepatectomy on the Safety and Efficacy of Radioembolization With Yttrium-90 Microspheres for Patients With Unresectable Liver Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 454-460.	0.6	22

#	Article	IF	CITATIONS
19	The importance of gender in patients with peritoneal metastases of appendiceal origin treated by cytoreduction and intraperitoneal chemotherapy: an analysis of 257 consecutive patients from an Australian centre. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1037-1045.	1.2	4
20	Efficacy of a novel mucolytic agent on pseudomyxoma peritonei mucin, with potential for treatment through peritoneal catheters. American Journal of Cancer Research, 2014, 4, 495-507.	1.4	3
21	Summary outcomes of twoâ€stage resection for advanced colorectal liver metastases. Journal of Surgical Oncology, 2013, 107, 211-216.	0.8	43
22	Summary of current therapeutic options for peritoneal metastases from colorectal cancer. Journal of Surgical Oncology, 2013, 107, 566-573.	0.8	59
23	Comparative analysis of perioperative intraperitoneal chemotherapy regimen in appendiceal and colorectal peritoneal carcinomatosis. International Journal of Clinical Oncology, 2013, 18, 439-446.	1.0	43
24	Cure for peritoneal metastases? An evidenceâ€based review. ANZ Journal of Surgery, 2013, 83, 821-826.	0.3	6
25	Peritoneal metastases of lower gastrointestinal tract origin: a comparative study of patient outcomes following cytoreduction and intraperitoneal chemotherapy. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1899-1908.	1.2	35
26	Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases. Journal of Surgical Oncology, 2013, 108, 81-88.	0.8	36
27	Radioembolisation with <scp>Y</scp> ttriumâ€90 microspheres: An effective treatment modality for unresectable liver metastases. Journal of Medical Imaging and Radiation Oncology, 2013, 57, 72-80.	0.9	28
28	Does the expression of BCL2 have prognostic significance in malignant peritoneal mesothelioma?. American Journal of Cancer Research, 2013, 3, 312-22.	1.4	6
29	Ki67-BCL2 index in prognosis of malignant peritoneal mesothelioma. American Journal of Cancer Research, 2013, 3, 411-23.	1.4	7
30	Surgery for colorectal peritoneal carcinomatosis. Scandinavian Journal of Gastroenterology, 2012, 47, 277-285.	0.6	13
31	Optimizing the Surgical Effort in Patients With Advanced Neuroendocrine Neoplasm Hepatic Metastases. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 439-445.	0.6	16
32	Hepatic Resection for Transplantable Hepatocellular Carcinoma for Patients Within Milan and UCSF Criteria. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 141-145.	0.6	14
33	Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Journal of Clinical Oncology, 2012, 30, 2449-2456.	0.8	873
34	Inflammatory Markers in Blood and Serum Tumor Markers Predict Survival in Patients With Epithelial Appendiceal Neoplasms Undergoing Surgical Cytoreduction and Intraperitoneal Chemotherapy. Annals of Surgery, 2012, 256, 342-349.	2.1	56
35	Surgical resection of hepatic metastases from neuroendocrine neoplasms: A systematic review. Surgical Oncology, 2012, 21, e131-e141.	0.8	116
36	Hepatectomy and resection of concomitant extrahepatic disease for colorectal liver metastases – A systematic review. European Journal of Cancer, 2012, 48, 1757-1765.	1.3	58

#	Article	IF	CITATIONS
37	Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases – A systematic review. Surgical Oncology, 2012, 21, 299-308.	0.8	68
38	Radioembolization versus Standard Care of Hepatic Metastases: Comparative Retrospective Cohort Study of Survival Outcomes and Adverse Events in Salvage Patients. Journal of Vascular and Interventional Radiology, 2012, 23, 96-105.	0.2	122
39	Peritoneal Mesothelioma. Surgical Oncology Clinics of North America, 2012, 21, 635-643.	0.6	13
40	Diffuse malignant peritoneal mesothelioma – An update on treatment. Cancer Treatment Reviews, 2012, 38, 605-612.	3.4	71
41	Resectable Colorectal Liver Metastases: Optimal Sequencing of Chemotherapy. Journal of Gastrointestinal Cancer, 2012, 43, 496-498.	0.6	4
42	Colorectal Liver Metastases with Extrahepatic Disease—A New Criteria for Oncologic Resection?. Journal of Gastrointestinal Cancer, 2012, 43, 502-504.	0.6	3
43	Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy. Cancer Management and Research, 2012, 4, 413.	0.9	39
44	Liverâ€directed therapy for neuroendocrine neoplasm hepatic metastasis prolongs survival following progression after initial surgery. Journal of Surgical Oncology, 2012, 105, 342-350.	0.8	19
45	Clinicopathologic factors associated with HER2â€positive gastric cancer and its impact on survival outcomes—A systematic review. International Journal of Cancer, 2012, 130, 2845-2856.	2.3	157
46	Exploring the role of resection of extrahepatic metastases from hepatocellular carcinoma. Surgical Oncology, 2012, 21, 95-101.	0.8	64
47	Early recurrence of pseudomyxoma peritonei following treatment failure of cytoreductive surgery and perioperative intraperitoneal chemotherapy is indicative of a poor survival outcome. International Journal of Colorectal Disease, 2012, 27, 381-389.	1.0	42
48	Evolution of locoregional treatment for peritoneal carcinomatosis: single-center experience of 308 procedures of cytoreductive surgery and perioperative intraperitoneal chemotherapy. American Journal of Surgery, 2011, 201, 149-156.	0.9	24
49	<i>Development of a Bayesian Belief Network Model for Personalized Prognostic Risk Assessment in Colon Carcinomatosis</i> . American Surgeon, 2011, 77, 221-230.	0.4	31
50	Upfront Compared to Delayed Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Is Associated With Considerably Lower Perioperative Morbidity and Recurrence Rate. Annals of Surgery, 2011, 253, 769-773.	2.1	28
51	Outcomes of Single-Centre Experience of Hepatic Resection and Cryoablation of Sarcoma Liver Metastases. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 317-320.	0.6	17
52	Preoperative chemoradiation followed by surgical resection for resectable pancreatic cancer: A review of current results. Surgical Oncology, 2011, 20, e161-e168.	0.8	20
53	In Reply: Pseudomyxoma Peritonei: Debulk or Maximal Cytoreduction?. Annals of Surgical Oncology, 2011, 18, 284-285.	0.7	1
54	Surgical Management and Emerging Therapies to Prolong Survival in Metastatic Neuroendocrine Cancer. Annals of Surgical Oncology, 2011, 18, 222-223.	0.7	0

#	Article	IF	CITATIONS
55	Determining the Association Between Preoperative Computed Tomography Findings and Postoperative Outcomes After Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei. Annals of Surgical Oncology, 2011, 18, 1582-1589.	0.7	51
56	Influence of Modern Systemic Therapies as Adjunct to Cytoreduction and Perioperative Intraperitoneal Chemotherapy for Patients With Colorectal Peritoneal Carcinomatosis: A Multicenter Study. Annals of Surgical Oncology, 2011, 18, 1560-1567.	0.7	87
57	Surgical Cytoreduction and Survival in Appendiceal Cancer Peritoneal Carcinomatosis: An Evaluation of 46 Consecutive Patients. Annals of Surgical Oncology, 2011, 18, 1540-1546.	0.7	15
58	Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases. Journal of Cancer Research and Clinical Oncology, 2011, 137, 865-873.	1.2	48
59	Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: a comparative analysis. International Journal of Clinical Oncology, 2011, 16, 125-132.	1.0	16
60	Trends in surgical oncology research in Australia during the period 1998–2009—a bibliometric review. Journal of Surgical Oncology, 2011, 104, 216-219.	0.8	10
61	A novel tumorâ€nodeâ€metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multiâ€institutional database*. Cancer, 2011, 117, 1855-1863.	2.0	129
62	Palliative Effects of an Incomplete Cytoreduction Combined With Perioperative Intraperitoneal Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 568-571.	0.6	12
63	Treatments and Outcomes of Peritoneal Surface Tumors Through a Centralized National Service (United Kingdom). Diseases of the Colon and Rectum, 2010, 53, 1218-1219.	0.7	Ο
64	Morbidity and Mortality Outcomes of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy at a Single Tertiary Institution. Annals of Surgery, 2010, 251, 101-106.	2.1	74
65	Evaluation of the Cost-Effectiveness of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (Peritonectomy) at the St George Hospital Peritoneal Surface Malignancy Program. Annals of Surgery, 2010, 251, 323-329.	2.1	50
66	Factors Predicting Response and Survival After Yttrium-90 Radioembolization of Unresectable Neuroendocrine Tumor Liver Metastases. Annals of Surgery, 2010, 251, 910-916.	2.1	134
67	Yttrium-90 Radiotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Preliminary Assessment of This Novel Treatment Option. Annals of Surgical Oncology, 2010, 17, 484-491.	0.7	182
68	Systematic Review of Randomized and Nonrandomized Trials of the Clinical Response and Outcomes of Neoadjuvant Systemic Chemotherapy for Resectable Colorectal Liver Metastases. Annals of Surgical Oncology, 2010, 17, 492-501.	0.7	127
69	Impact of the Peritoneal Surface Disease Severity Score on Survival in Patients with Colorectal Cancer Peritoneal Carcinomatosis Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology, 2010, 17, 1330-1336.	0.7	70
70	Critical Assessment of Risk Factors for Complications After Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei. Annals of Surgical Oncology, 2010, 17, 1291-1301.	0.7	72
71	Impact of Tumor Angiogenesis in Peritoneal Mesothelioma After Radical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. Pathology and Oncology Research, 2010, 16, 217-222.	0.9	9
72	Extended Pancreaticoduodenectomy with Vascular Resection for Pancreatic Cancer: A Systematic Review. Journal of Gastrointestinal Surgery, 2010, 14, 1442-1452.	0.9	135

#	Article	IF	CITATIONS
73	Clinicopathologic and Treatment-Related Factors Influencing Recurrence and Survival after Hepatic Resection of Intrahepatic Cholangiocarcinoma: A 19-Year Experience from an Established Australian Hepatobiliary Unit. Journal of Gastrointestinal Surgery, 2010, 14, 1128-1138.	0.9	53
74	Secondary Cytoreduction and Perioperative Intraperitoneal Chemotherapy after Initial Debulking of Pseudomyxoma Peritonei: A Study of Timing and the Impact of Malignant Dedifferentiation. Journal of the American College of Surgeons, 2010, 211, 526-535.	0.2	23
75	Radiofrequency ablation as an adjunct to systemic chemotherapy for colorectal pulmonary metastases. Cancer, 2010, 116, 2106-2114.	2.0	45
76	Intraâ€arterial iodineâ€131â€lipiodol for unresectable hepatocellular carcinoma. Cancer, 2010, 116, 4069-4077.	2.0	24
77	Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. Liver International, 2010, 30, 166-174.	1.9	68
78	Salvage cytoreduction for chemorefractory ovarian cancer with peritoneal carcinomatosis: A last chance or futile efforts?. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2010, 50, 478-484.	0.4	2
79	Secondâ€line treatment of first relapse recurrent ovarian cancer. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2010, 50, 465-471.	0.4	5
80	Successful right hepatectomy after four treatments of yttrium-90 microspheres (SIR-Spheres) and concomitant FOLFOX as bridging therapy to resection of colorectal liver metastases. Anticancer Research, 2010, 30, 3005-7.	0.5	11
81	New treatments and outcomes in peritoneal carcinomatosis. Medical Journal of Australia, 2009, 191, 3-4.	0.8	3
82	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience. Journal of Clinical Oncology, 2009, 27, 6237-6242.	0.8	598
83	Towards randomized trials of cytoreductive surgery using peritonectomy and hyperthermic intraperitoneal chemotherapy for ovarian cancer peritoneal carcinomatosis. Gynecologic Oncology, 2009, 114, 137-139.	0.6	19
84	Establishing evidence for change in ovarian cancer surgery — Proposing clinical trials of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis. Gynecologic Oncology, 2009, 115, 166-168.	0.6	14
85	Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: The Australian experience. Journal of Surgical Oncology, 2009, 99, 109-113.	0.8	72
86	Thoracic cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy for pseudomyxoma peritonei. Journal of Surgical Oncology, 2009, 99, 292-295.	0.8	18
87	Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma. Journal of Surgical Oncology, 2009, 100, 139-143.	0.8	29
88	Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. Journal of Cancer Research and Clinical Oncology, 2009, 135, 1637-1645.	1.2	169
89	Significance of Lymph Node Metastasis in Patients with Colorectal Cancer Peritoneal Carcinomatosis. World Journal of Surgery, 2009, 33, 1488-1494.	0.8	22
90	The St George Hospital Peritoneal Surface Malignancy Program – where are we now?. ANZ Journal of Surgery, 2009, 79, 416-418.	0.3	7

#	Article	IF	CITATIONS
91	Gastrointestinal oncological surgery in patients with metastatic cancer treated with angiogenesis inhibitors: safe or not?. ANZ Journal of Surgery, 2009, 79, 672-673.	0.3	2
92	Long-Term Survival in Patients with Pseudomyxoma Peritonei Treated with Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy: 10ÂYears of Experience from a Single Institution. Annals of Surgical Oncology, 2009, 16, 1903-1911.	0.7	109
93	Pseudomyxoma Peritonei: A Need to Establish Evidence-Based Standard of Care—Is This the Right Trial?. Annals of Surgical Oncology, 2009, 16, 2675-2677.	0.7	8
94	Results of systemic pemetrexed-based combination chemotherapy versus cytoreductive surgery and hyperthermic intraperitoneal cisplatin and doxorubicin on survival in malignant peritoneal mesothelioma. Lung Cancer, 2009, 66, 269-270.	0.9	9
95	Diffusion Tensor Imaging of the Posterior Cingulate is a Useful Biomarker of Mild Cognitive Impairment. American Journal of Geriatric Psychiatry, 2009, 17, 602-613.	0.6	68
96	Should the Treatment of Peritoneal Carcinomatosis by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Still be Regarded as a Highly Morbid Procedure?. Annals of Surgery, 2009, 249, 900-907.	2.1	479
97	Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management. Canadian Journal of Surgery, 2009, 52, 59-64.	0.5	30
98	In vivo model of pseudomyxoma peritonei for novel candidate drug discovery. Anticancer Research, 2009, 29, 4051-5.	0.5	6
99	Diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease: a review. Current Opinion in Neurology, 2008, 21, 83-92.	1.8	251